A Phase 1, Randomized, Double-Blind, Placebo Controlled, Dose-Escalation Study Investigating the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of CB-0406 Tablets in Healthy Volunteers
Latest Information Update: 02 Nov 2021
At a glance
- Drugs CB 0406 (Primary)
- Indications Inflammation
- Focus Pharmacokinetics
- Sponsors CymaBay Therapeutics
- 10 Jun 2021 Status changed from recruiting to completed.
- 08 Jan 2021 Status changed from not yet recruiting to recruiting.
- 17 Jul 2020 New trial record